What triggers cause hemolytic reactions in patients with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

What Triggers Hemolytic Reactions in G6PD Deficiency

Hemolytic reactions in G6PD deficiency are triggered by oxidant drugs, infections, and certain foods (notably fava beans), with the most clinically important medication triggers being dapsone, primaquine, sulfonamides, rasburicase, and methylene blue 1.

Mechanism of Hemolysis

G6PD deficiency is an X-linked genetic disorder where red blood cells lack adequate protective mechanisms against oxidative stress. The G6PD enzyme is essential for producing NADPH through the hexose monophosphate shunt, which protects erythrocytes from reactive oxygen species 2. When deficient, exposure to oxidizing agents causes rapid red blood cell destruction, resulting in acute hemolytic anemia.

Primary Medication Triggers

High-Risk Oxidant Drugs

The following medications are well-established triggers that should be avoided in G6PD-deficient patients:

• Antimalarials: Primaquine, tafenoquine 3
• Antibiotics: Dapsone, sulfonamides (including sulfamethoxazole), nitrofurantoin 1, 2
• Oncologic agents: Rasburicase 2
• Diagnostic/therapeutic agents: Methylene blue 4
• Local anesthetics: Benzocaine, particularly in teething gels for infants 4
• Other medications: Chloramphenicol, high-dose aspirin, phenazopyridine 2

Medium-Risk Medications

Use with extreme caution and close monitoring:

• Metronidazole and tetracycline (as part of H. pylori quadruple therapy) 5
• Quinine (though safer than primaquine for malaria treatment) 3

Variant-Specific Risk Stratification

The severity of hemolysis depends critically on the G6PD variant 1, 6:

• GdMed variant (Mediterranean, Indian, Southeast Asian populations): Life-threatening hemolysis; absolute contraindication to oxidant drugs
• GdA− variant (10-15% of Black individuals): Milder, self-limited hemolysis that may not always preclude oxidant drug use with careful monitoring

This distinction is clinically crucial—the same medication may be manageable in one variant but fatal in another.

Non-Medication Triggers

Infections

Oxidative stress from infections themselves can precipitate hemolysis, independent of treatment 7.

Foods

Fava beans (broad beans) are a well-known dietary trigger, particularly in Mediterranean populations 8.

Topical Exposures

Henna dye applied topically can cause severe intravascular hemolysis, especially in children 8. This is an often-overlooked trigger that shares structural similarities with other oxidant agents.

Special Clinical Scenarios

Primaquine Use in Malaria

In populations where severe G6PD deficiency is common (notably Asians), primaquine should not be administered for more than 5 days due to risk of life-threatening hemolysis 3. Whenever possible, G6PD testing should precede primaquine administration.

Methylene Blue Paradox

Methylene blue presents a unique problem: it is both the primary treatment for methemoglobinemia AND a potent hemolytic trigger in G6PD deficiency 4. In G6PD-deficient patients, methylene blue is contraindicated and may paradoxically worsen methemoglobinemia while causing severe hemolysis. Alternative treatments (ascorbic acid, exchange transfusion) must be used instead.

Pregnancy and Fetal Considerations

G6PD deficiency can cause nonimmune hydrops fetalis and severe fetal anemia when mothers are exposed to oxidant substances during pregnancy 7. Both male and female fetuses can be affected, despite the X-linked inheritance pattern.

Clinical Pitfalls to Avoid

1. Don't assume female patients are protected: While X-linked, females can have full deficiency and severe hemolysis 8, 7

2. Don't rely on family history alone: Screen high-risk populations (Mediterranean, African, Asian descent) before prescribing oxidant drugs 1

3. Don't overlook non-pharmaceutical triggers: Question about henna use, fava bean consumption, and recent infections 8

4. Don't use methylene blue emergently without considering G6PD status: In emergency methemoglobinemia treatment, obtain family history of G6PD deficiency before administering methylene blue 4

Screening Recommendations

Screen for G6PD deficiency before initiating oxidant drug therapy in patients with predisposing racial or ethnic backgrounds (strong recommendation) 1. This includes:

• Black/African descent (10-15% prevalence)
• Mediterranean populations
• Middle Eastern populations
• Southeast Asian populations

The hemolysis can develop within hours of exposure 5, making preemptive screening essential rather than reactive testing.